ClinicalTrials.gg
Not yet recruitingNCT07293728Updated Nov 19, 2026

Comparing Drospirenone and Norethindrone for Postpartum Hypertension Management in Preeclampsia

A Phase 4 interventional study of Norethindrone 0.35 MG and Drospirenone in Hypertension and Preeclampsia, sponsored by Oregon Health and Science University. Not yet recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Primary conditionPre-EclampsiaRegistry: HypertensionReclassifiedWhy we changed it
Registry
Hypertension — the first condition term the registry derived for this study.
ClinicalTrials.gg
Pre-Eclampsia
Why
  1. The study's listed conditions name Pre-Eclampsia, a narrower term within Hypertension.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Oregon Health and Science University · Phase 4, Interventional, and Treatment

How we know

Updated Nov 19, 2026Start date movedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 230 studies in Pre-Eclampsia with a site in United States — 62 open to participants now, 78 under way, 6 of them phase 3. Pre-Eclampsia · United States.

Planned enrollment
107th of 161
50 · median 89
Started
2027
with 3 others
Phase 4
31 of 230
11 open now
Primary completion
2027-12
later than 48 of 77 live
Registered
211th of 230
by date

Among the 230 studies in Pre-Eclampsia with a site in United States, this one is the 107th largest by planned enrollment of the 161 interventional ones that give a count, is one of 4 that started in 2027, is one of 31 in phase 4, reaches primary completion later than 48 of the 77 other live ones, and was the 211th registered.

Pre-Eclampsia

918 studies on the registry are indexed under Pre-Eclampsia; 243 are open to participants now.

Browse Pre-Eclampsia studies →

Open to participants now

62 of the 230 studies in Pre-Eclampsia with a site in United States are open now. Recruiting first, the newest first:

57 more — sign in →

All 62 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 160 Pre-Eclampsia studies recruiting now, 79 (49%) set no upper age limit and 80 (50%) stop at 75 or younger; 18 take children under 18; 59 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 230 studies in Pre-Eclampsia with a site in United States, or all of them as a file.
02

Study summary

This is an open-label, randomized feasibility trial in which participants admitted to Oregon Health \& Science University (OHSU) after a pregnancy complicated by preeclampsia who are considering a progestin-only pill contraception postpartum will be randomized to norethindrone or drospirenone for 6 weeks following hospital discharge.

Read the detailed description

In this open-label, randomized, feasibility trial, investigators will recruit participants admitted to OHSU after a pregnancy complicated preeclampsia (diagnosed antepartum or postpartum). All patients admitted after a birth are offered contraception as a routine part of clinical care; only prospective participants who are undecided in their birth control method or who are considering a progestin-only pill contraception will be approached for inclusion.

Participants who consent for enrollment will be randomized to norethindrone or drospirenone. Prescriptions will be filled by the OHSU research pharmacy and delivered to patients prior to discharge. Participants will then receive weekly emails to report medication adherence, home-measured blood pressures (typical standard of care for preeclampsia), and any interval changes in medication or unscheduled healthcare encounters. Follow up will continue through six weeks, consistent with typical close blood pressure monitoring for postpartum patients with preeclampsia. Participants accessing drospirenone through the study who desire to continue after conclusion will be provided with information for obtaining a prescription from their primary provider as well as manufacturer information to reduce prescription costs (as prior authorization requirements are more common with this medication).

03

Conditions studied

  • Hypertension
  • Preeclampsia

Browse trials for

Keywords

  • Postpartum Hypertension Management
04

In context

Pre-Eclampsia Reclassified

918 studies on the registry are indexed under Pre-Eclampsia; 243 are open to participants now.

This study's planned enrollment of 50 is below the median of 110 across 482 interventional studies indexed under Pre-Eclampsia.

Browse Pre-Eclampsia studies →

Lead sponsor

Oregon Health and Science University is the lead sponsor of 697 studies on the registry; 129 are open to participants now.

Of its 53 completed or terminated interventional studies of FDA-regulated products, 39 (74%) have results posted.

Compared within Pre-Eclampsia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hypertension. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Admission to Oregon Health \& Science University following a birth (during the same admission)
  • A diagnosis of preeclampsia or chronic hypertension with superimposed preeclampsia (with or without severe features)
  • Considering use of a progestin-only pill for postpartum

Exclusion criteria

Exclusion Criteria:

  • Planned use of a method other than a progestin-only pill
  • to drospirenone or norethindrone
  • Inability to monitor blood pressure at home after discharge
  • Inability to complete follow-up surveys by email in English
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

06

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Active comparator
    Postpartum Norethindrone

    Norethindrone is a well-established progestin-only contraceptive that is considered standard of care for postpartum contraception, particularly in breastfeeding individuals. Norethindrone serves as the comparator arm representing the current standard practice for postpartum contraception in individuals with recent hypertensive disorders of pregnancy.

    Drug: Norethindrone 0.35 MG

  • Experimental
    Postpartum Drospirenone

    Drospirenone is a newer progestin-only contraceptive approved by the FDA that exhibits mineralocorticoid receptor activity that has been shown to modestly lower blood pressure in addition to serve as contraception. Drospirenone represents a novel therapeutic option that may offer superior blood pressure outcomes in postpartum individuals with hypertensive disorders unlike other progestin-only contraceptives.

    Drug: Drospirenone

Interventions

  • DrugNorethindroneStudies of NorethindroneNorethindrone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    1 tablet (0.35 mg) once daily, taken at the same time each day between hospital discharge following delivery until 6 weeks postpartum.

  • 1 tablet (4 mg) once daily for 24 days, followed by 4 inactive tablets. Repeated from hospital discharge following delivery until 6 weeks postpartum.

07

What researchers measure

Primary outcomes

  1. Blood Pressure

    Arterial, systolic, and diastolic blood pressure will be compared between norethindrone and drospirenone users. Measured by participants at home and reported in weekly surveys.

    Time frame: Measured weekly for the 6 weeks following delivery.

Secondary outcomes

  1. Antihypertensive Medications

    The proportion of participants requiring up titration or new initiation of antihypertensive medications after discharge from the hospital. Measured by weekly survey.

    Time frame: Collected weekly for the 6 weeks following delivery.

  2. Follow-Up Visits

    The number of participants requiring unscheduled in-person assessment of blood pressure concerns or readmission to the hospital relating to blood pressure concerns. Will be measured using weekly participant surveys.

    Time frame: Assessed weekly between delivery and 6 weeks postpartum.

08

Study locations

1 site
09

References and documents

Individual participant data

Plan to share: No — There is no plan at this time to share individual participant data with other researchers.

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Dec 2027, 11 months later.

Of 35 phase 4 interventional studies under Pre-Eclampsia, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 35. This study's planned 11 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 19, 2026: start Jul 2026 → Jan 2027, primary completion Dec 2026 → Dec 2027 and completion Dec 2026 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2025
First posted
Dec 19, 2025
StartEst.
Jan 2027was Jul 2026
Primary completionEst.
Dec 2027was Dec 2026
CompletionEst.
Dec 2027was Dec 2026
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jul 2026→Jan 2027
Nov 19, 2026
Primary completion
Dec 2026→Dec 2027
Nov 19, 2026
Study completion
Dec 2026→Dec 2027
Nov 19, 2026
Title
A Randomized Feasibility Trial Comparing Drospirenone and Norethindrone for Postpartum Hypertension Management in Preeclampsia
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Start date Jul 2026→Jan 2027
    Primary completion Dec 2026→Dec 2027
    Study completion Dec 2026→Dec 2027
    Title A Randomized Feasibility Trial Comparing Drospirenone and Norethindrone for Postpartum Hypertension Management in Preeclampsia
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07293728
Responsible party
Julia Tasset (Principal Investigator, Oregon Health and Science University) — Principal investigator
First posted
Dec 19, 2025
Start date
Jan 2027 (estimated)
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 19, 2026

Study contacts

Women's Health Research Unit Department of OB/Gyn
Contact
whru@ohsu.edu
503-494-3666
Julia Tasset
principal investigator · Oregon Health and Science University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Drospirenone

Start the discussion